Preoperative exercise therapy for gastrointestinal cancer patients: a systematic review

Table 1 Summary of patient characteristics

Study	Patient population	Groups	N	Age (year)	% male	ASA > II	BMI (kg/m²)
Carli et al.	Benign or malignant colorectal cancer	Intervention	58	61 ± 16	59	22%	28 ± 6
Carli et al.	Benign or malignant colorectal cancer	Control	54	60 ± 15	57	20%	27 ± 5
Cho et al.	Gastric cancer	Intervention	18	63.1 (51–76)*	100	NR	26.7 (23.1–31.2)*
Cho et al.	Gastric cancer	Control	54	66.1 (39–81)*	94.4	NR	25.7 (20.8–34.1)*
Dronkers et al.	Colon cancer	Intervention	22	71.1 ± 6.3	68.2	NR	26.6 ± 3.6
Dronkers et al.	Colon cancer	Control	20	68.8 ± 6.4	80	NR	25.6 ± 3.1
Gillis et al.	Colorectal cancer	Intervention	38	65.7 ± 13.6	55	26%	26.9 ± 4.6
Gillis et al.	Colorectal cancer	Control	39	66.0 ± 9.1	69	23%	28.5 ± 4.3
Kaibori et al.	Hepatocellular carcinoma	Intervention	25	68 ± 9.1	68	NR	NR
Kaibori et al.	Hepatocellular carcinoma	Control	26	71.3 ± 8.8	73	NR	NR
Kim et al.	Benign or malignant colorectal cancer	Intervention	14	55 ± 15	64	NR	26.6 ± 5.9
Kim et al.	Benign or malignant colorectal cancer	Control	7	65 ± 9	57	NR	25.3 ± 2.7
Li et al.	Colorectal cancer	Intervention	42	67.4 ± 11	54	19%	27.5 ± 4
Li et al.	Colorectal cancer	Control	45	66.4 ± 12	64	22%	26.9 ± 6
West et al.	Rectal cancer treated with NACRT	Intervention	22	64 (45–82)*	64	9%	NR
West et al.	Rectal cancer treated with NACRT	Control	13	72 (62–84)	69	15%	NR
Dunne et al.	Colorectal liver metastasis	Intervention	20	61 (56–66)*	65	NR	29.2 ± 4.1
Dunne et al.	Colorectal liver metastasis	Control	17	62 (53–72)*	77	NR	29.3 ± 4.2

Age and BMI values are presented as mean ± standard deviation, unless otherwise noted
*Range reported, rather than standard deviation
NACRT neoadjuvant chemoradiotherapy, NR not reported, BMI body mass index, ASA American Society of Anesthesiologist class

ISSN: 2046-4053